230 related articles for article (PubMed ID: 34091209)
21. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
22. Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors.
Xiao Z; Chu C; Zhou L; Zhou Z; Zhang Q; Yang F; Yang Z; Zheng P; Xu S; Zhu W
Bioorg Med Chem; 2020 Oct; 28(19):115669. PubMed ID: 32912435
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL
Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of 1H-pyrazolo [3,4-d]pyrimidine derivatives as PAK1 inhibitors that trigger apoptosis, ER stress and anti-migration effect in MDA-MB-231 cells.
Zhang J; Zou L; Tang P; Pan D; He Z; Yao D
Eur J Med Chem; 2020 May; 194():112220. PubMed ID: 32222676
[TBL] [Abstract][Full Text] [Related]
27. 2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights.
Elbadawi MM; Eldehna WM; Abd El-Hafeez AA; Somaa WR; Albohy A; Al-Rashood ST; Agama KK; Elkaeed EB; Ghosh P; Pommier Y; Abe M
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):349-372. PubMed ID: 34923887
[TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis and Biological Evaluation of a Novel Series of Thiadiazole- Based Anticancer Agents as Potent Angiogenesis Inhibitors.
Altuğ-Tasa B; Kaya-Çavuşoğlu B; Koparal AT; Turan G; Koparal AS; Kaplancıklı ZA
Anticancer Agents Med Chem; 2021; 21(15):2041-2049. PubMed ID: 33390125
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
Metwally NH; Mohamed MS; Ragb EA
Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
[TBL] [Abstract][Full Text] [Related]
30. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
[TBL] [Abstract][Full Text] [Related]
32. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines.
Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM
Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475
[TBL] [Abstract][Full Text] [Related]
34. Anti-angiogenic effects of novel cyclin-dependent kinase inhibitors with a pyrazolo[4,3-d]pyrimidine scaffold.
Zhang S; Ulrich M; Gromnicka A; Havlíček L; Kryštof V; Jorda R; Strnad M; Vollmar AM; Zahler S
Br J Pharmacol; 2016 Sep; 173(17):2645-56. PubMed ID: 27390037
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, structure-activity relationships and biological evaluation of barbigerone analogues as anti-proliferative and anti-angiogenesis agents.
Wang G; Wang F; Cao D; Liu Y; Zhang R; Ye H; Li X; He L; Yang Z; Ma L; Peng A; Xiang M; Wei Y; Chen L
Bioorg Med Chem Lett; 2014 Jul; 24(14):3158-63. PubMed ID: 24863745
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of novel 2,4-bismorpholinothieno[3,2-d]pyrimidine and 2-morpholinothieno[3,2-d]pyrimidinone derivatives as potent antitumor agents.
Ye T; Han Y; Wang R; Yan P; Chen S; Hou Y; Zhao Y
Bioorg Chem; 2020 Jun; 99():103796. PubMed ID: 32283346
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of novel benzylidene-succinimide derivatives as noncytotoxic antiangiogenic inhibitors with anticolorectal cancer activity in vivo.
Luo K; Bao Y; Liu F; Xiao C; Li K; Zhang C; Huang R; Lin J; Zhang J; Jin Y
Eur J Med Chem; 2019 Oct; 179():805-827. PubMed ID: 31295714
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
Li R; Gong L; Sun J; Liang Z; He J; Huang J; Ning X; Song H; Li R; Zhang Q; Lin Z; Yin Y
Bioorg Chem; 2024 Mar; 144():107134. PubMed ID: 38237389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
